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Recent publications suggest that the Parkinson’s disease- (PD-) related PINK1/Parkin pathway promotes elimination of
dysfunctional mitochondria by autophagy. We used tandem aﬃnity puriﬁcation (TAP), SDS-PAGE, and mass spectrometry as
a ﬁrst step towards identiﬁcation of possible substrates for PINK1. The cellular abundance of selected identiﬁed interactors was
investigated by Western blotting. Furthermore, one candidate gene was sequenced in 46 patients with atypical PD. In addition to
two known binding partners (HSP90,CDC37), 12 proteins were identiﬁed using the TAP assay;four of which are mitochondrially
localized (GRP75, HSP60, LRPPRC, and TUFM). Western blot analysis showed no diﬀerences in cellular abundance of these
proteins comparing PINK1 mutant and control ﬁbroblasts. When sequencing LRPPRC, four exonic synonymous changes and
20 polymorphisms in noncoding regions were detected. Our study provides a list of putative PINK1 binding partners, conﬁrming
previouslydescribed interactions,butalsointroducingnovelmitochondrialproteinsaspotentialcomponentsofthePINK1/Parkin
mitophagy pathway.
1.Introduction
Parkinson’s disease (PD) is a progressive neurodegenerative
disorder with three cardinal manifestations: tremor, rigidity,
and bradykinesia. In about 25% of all PD patients, at least
one additional aﬀected family member can be found, likely
pointing to a direct, genetic cause of the disease. To date,
eight genes have been conﬁrmed to be associated with PD
[1].
Besides the mutational analysis of PD-linked genes,
the search for potential interactions between the protein
productsofthesegeneshasrecentlygainedincreasingimpor-
tance. Since the identiﬁcation of the second monogenetic
PD gene product Parkin, a common pathway leading to
dopaminergic neurodegeneration has been proposed. To
date, several studies reported such connections.
First, Shimura et al. hypothesized that Parkin plays a role
in the coregulation of Alpha-synuclein (SNCA). The group
identiﬁed a protein complex in normal human brain that
includedthe E3ubiquitinligase Parkin, UBCH7as its associ-
ated E2 ubiquitin-conjugating enzyme, and a novel form of
SNCA as its substrate [2]. Later, an early-onset PD patient
with a heterozygous missense mutation in both the DJ-1 and
the PTEN-induced putative kinase 1 (PINK1) gene has been
described. Additionally, overexpression of DJ-1 and PINK1
in SHSY-5Y cells revealed that the wildtype as well as the
mutant forms of both proteins interact, and DJ-1 stabilized
PINK1 [3]. Furthermore, Drosophila pink1 and parkin loss-
of-function mutants showed a similar mitochondrial pheno-
type. Since the pink1-related abnormalities could be rescued
by parkin overexpression but not vice versa, it was suggested
thatpink1actsupstream ofparkin in acommonpathway[4–
6]. Recent studies provided evidence that the PINK1/Parkin
pathway promotes mitochondrial ﬁssion as an initial step of
mitophagy by ubiquitination of Mitofusins [7–9].
Still, only the minority of hereditary forms of PD can be
explained by a mutation in one of the nine PD-associated2 Parkinson’s Disease
genes [10]. Therefore, this research focuses not only on
proteins known to be involved in PD but also on novel
interactors.
In the present study, we employed tandemaﬃnity puriﬁ-
cation (TAP) to isolate proteins that are directly associated
with PINK1. Using this approach, we aimed at a better
characterization of the PINK1/Parkin mitophagy pathway.
2.MaterialandMethods
2.1. Patients. All patients underwent a standardized neu-
rological examination performed by a movement disorders
specialist. For sequencing of one of the candidate genes,
Leucine-rich PPR motif-containing (LRPPRC), 46 patients
with atypical Parkinsonism including features of dementia,
depression, orrapid disease progression were includedin the
presentstudy.Afterobtaininginformedconsent,wecollected
blood from all patients for DNA extraction according to a
published protocol [11].
Furthermore, ﬁbroblasts from three PD patients with a
homozygous p.Q456X PINK1 mutation and from two age-
matched mutation-negative healthy controls were included
in the study. Clinical features of these mutation carriers are
described elsewhere [12, 13].
2.2. Tissue Culture. HEK cells and ﬁbroblasts were cultured
in Dulbecco’s modiﬁed Eagle’s medium (PAA Laboratories)
and supplemented with 10% fetal bovine serum and 1%
penicillin-streptomycin. All cells were maintained at 37◦C
in a saturated humidity atmosphere containing 5% CO2.
Passage numbers <10 were used for all experiments. To
inhibit the mitochondrial membrane potential, ﬁbroblasts
were treated with the potassium ionophore valinomycin
(1μM, Sigma).
2.3. Protein Isolation by TAP and Mass Spectrometry (MS).
The InterPlay Mammalian TAP System was employed
according to the manufacturer’s (Stratagene) protocol. In
brief, human control RNA was extracted using the RNeasy
Mini Kit (Qiagen) and PINK1 cDNA was synthesized using
Superscript II Reverse Transcriptase in combination with
oligo dT primers (Invitrogen). Full-length PINK1 cDNAwas
clonedinto the pCTAP expression vector, which encodestwo
tandem aﬃnity tags (a streptavidin binding peptide and a
calmodulin binding peptide) after its multiple cloning site.
Next, 108 HEK cells were transiently transfected with the
pCTAP-PINK1 vector by means of the Ca2+PO4 method
[14]. After 24h, cells were harvested and resuspended in
lysis buﬀer supplemented with protease inhibitors (Sigma).
Cells underwent three rounds of freeze-thawing, cell debris
was pelleted by centrifugation at 16,000×gf o r1 0m i n ,a n d
the supernatant collected. Next, 2mM EDTA, 10mM β-
mercaptoethanol, and the InterPlay streptavidin resin were
added to the cell lysate and incubated at 4◦C while rotating
for 2h. The resin was collected by centrifugation at 1,500×g
for 5min, washed twice, and incubated in biotin-containing
buﬀer for 30min at 4◦C to elute the bound protein com-
plexes. To further purify the protein complexes, calmodulin
resin and a calcium-containing buﬀer were added to the
supernatant. After 2h of incubation at 4◦C, the resin was
collected (centrifugation at 1,500×gf o r5m i n )a n dw a s h e d
twice. From the calmodulin resin, protein complexes were
eluted by adding EDTA-containing buﬀer and incubation
for 30min at 4◦C on a rotator. The resulting eluate
was concentrated by means of trichloroacetic precipitation
and subsequentlyresuspended inradioimmunoprecipitation
assay (RIPA) buﬀer (50mM Tris-HCl pH7.6, 150mM NaCl,
1% DOC, and 1% NP-40) with protease and phosphatase
inhibitors (Roche Diagnostics). Next, puriﬁed proteins were
resolved by one-dimensional SDS-polyacrylamide gel elec-
trophoresis (SDS-PAGE) and visualized on the gel by silver
staining as published [15]. In a control experiment, the pull-
downapproachwasperformedwithbeadsonly.Bandswhich
appeared on the gel from the PINK1 overexpression experi-
ment but not the control experiment were excised and sent
for MS analysis to the Taplin Biological Mass Spectrometry
Facility, Harvard Medical School, Boston, USA.Accordingto
the quality requirements of the facility, a protein can only be
considered as interactor if two or more peptides match the
respective protein in the Swiss-Prot database.
2.4. Knock-down Approach. For PINK1 and LRPPRC knock-
down, Hs PINK1 4 HP (Qiagen) and LRPPRC UTR (com-
plementary to the segment of the 3 UTR region of LRP-
PRC [16]) siRNAs were used with a ﬁnal concentration
of 50nM. Scrambled siRNA (Silencer negative control 1
siRNA [Ambion]) with no known mammalian homology
served as negative control (ﬁnal concentration 50nM). For
transfection, the Nucleofector Device (Lonza) was used.
2.5. Mitochondrial Preparation. Mitochondria were isolated
from ﬁbroblasts as previously described [17]. In brief,
cells were harvested and homogenized in buﬀer containing
250mM sucrose, 10mM Tris, and 1mM EDTA, pH7.4.
After that, nuclei and unbroken cells were removed by
centrifugation at 1,500×g for 20min. The supernatant
containing intact mitochondria was transferred into a new
tube and centrifuged at 12,000×g for 10min. The resulting
supernatant (cytosolicfraction) was transferred into another
new tube and the mitochondria-enriched pellet (mitochon-
drial fraction) was dissolved in RIPA buﬀer containing
protease and phosphatase inhibitors (Roche Diagnostics).
Cytoplasmic fractions were concentrated by using Centricon
YM-10 devices (Millipore) according to the manufacturer’s
instructions.
2.6. Protein Extraction. Proteins were extracted using RIPA
buﬀercontaining 0.1%SDS.Cellsor mitochondria-enriched
pellets were dissolved in the appropriate amount of buﬀer
and incubated on ice for 30min. After that, the lysates were
centrifuged at 16,000×gf o r2 0m i na t4 ◦C. The supernatant
was transferred into a new tube for further processing.
2.7. Western Blot Analysis. SDS-PAGE was performed using
NuPAGE 4%–12% Bis-Tris gels (Invitrogen). After elec-
trophoresis, proteins were transferred to the nitrocelluloseParkinson’s Disease 3
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Figure 1: SDS-PAGE result after TAP with overexpressed PINK1. (a) A TAP approach was performed with HEK cells overexpressing PINK1
(PINK1+). Puriﬁed proteins were resolved by SDS-PAGE and visualized on the gel by silver staining. Protein bands which were excised from
the gel are marked by an arrow head (a–g). (b) In a control experiment, the pull-down approach was performed with beads only (PINK1−).
A molecular weight marker was used to estimate the size of the detected protein bands.
membrane (Protran) and probed with antibodies raised
against β-actin (Sigma), Mortalin (GRP75, Abcam), Heat
shock 60kDa protein (HSP60, Cell Signalling), Mitochon-
drially encoded cytochrome c oxidase I (MT-CO1, Mito-
Sciences), Voltage-dependent anion channel 1 (VDAC1,
Abcam)andElongationfactorTU(TUFM,Abcam).Ananti-
body against LRPPRC was kindly provided by Professor S.
Pi˜ nol-Roma, Brookdale Department of Molecular, Cell and
Developmental Biology, Mount Sinai School of Medicine,
New York, USA [18].
2.8. Mutational Screening. All 38 coding LRPPRC exons
and ﬂanking intronic regions were sequenced on an ABI
3100 Genetic Analyzer. Primers and PCR conditions are
summarized in Supplementary Table 1 available online at
doi:10.4061/2011/153979.
3.Resultsand Discussion
3.1. New PINK1 Interactors. Using a TAP approach with
overexpressed PINK1 (PINK1+), or empty beads (PINK1−)
we identiﬁed interactors of the target protein. The resulting
TAP eluates were resolved by SDS-PAGE. Silver staining was
used to visualize protein bands on the PAGE gels. Seven
bands were excised from the PINK1+ gel (Figure 1(a),a – g )
which were not detectable on the PINK1− gel (Figure 1(b))
and analyzed by MS (Table 1).
A total of 14 proteins were identiﬁed which met the
requirement of having two or more peptides matched to
it by the database-searching program. Out of those, seven
are predominantly found in the cytoplasm (Heat shock
90kDa proteins alpha and beta, Heat shock 70kDa proteins
1, 2, 8, and 1-like, and Hsp90 cochaperone Cdc37), two
are components of microtubuli (Tubulin alpha-1C chain
and Tubulin alpha-3C/D chain), one is associated with the
endoplasmic reticulum (78kDa Glucose-regulated protein)
and four are mitochondrially localized (GRP75, HSP60,
LRPPRC, and TUFM) (for details on subcellular localization
see: http://expasy.org/sprot/). Of note, also PINK1 itself was
identiﬁed by MS in most of the analyzed bands on the PAGE
gel (Figure 1(a),b – g ) .
To our knowledge, only the interaction between the
HSP90/CDC37 chaperone system and PINK1 has been
described so far [19, 20]. CDC37 is a molecular cochap-
erone that functions with HSP90 to promote folding
of kinases [21]. With respect to PINK1, the chaperone
system was found to inﬂuence the protein’s subcellular
distribution. The authors of this study proposed that the
HSP90/CDC37/PINK1 complex is destined for a transloca-
tion that leads to PINK1 processing, whereas in the absence
of HSP90 in the complex, PINK1 might be attached to
mitochondria as full-length precursor [19].
Given that PINK1 was reported to be associated with
mitochondria [17, 22], we focused primarily on the mito-
chondrial proteins GRP75, HSP60, LRPPRC, and TUFM in
the ensuing experiments.
3.2. Cellular Abundance of GRP75, HSP60, LRPPRC, and
TUFM. First, we determined the quality of the noncommer-
cially available LRPPRCantibody by means ofa knock-down4 Parkinson’s Disease
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Figure 2: Speciﬁcity of an anti-LRPPRC antibody. Fibroblasts were
incubated withPINK1 siRNA,LRPPRC siRNA,orscrambledsiRNA
for 24h. Whole cell lysates were analyzed by Western blotting
with an antibody against LRPPRC. LRPPRC levels decreased only
when LRPPRC siRNA was employed, conﬁrming the speciﬁcity of
the anti-LRPPRC antibody used in our study. The mitochondrial
markers HSP60 and VDAC1 served as loading controls. HSP60:
Heat shock 60kDa protein; LRPPRC: Leucine-rich PPR motif-
containingprotein; VDAC1: Voltage-dependent anion channel 1.
approach. This experiment showed a drop in LRPPRC levels
when siRNA against LRPPRC was employed but not when
scrambled siRNA was used, conﬁrming the speciﬁcity of the
antibody. LRPPRC protein levels were also not aﬀected by a
PINK1 knockdown (Figure 2).
Next, the abundance of GRP75, HSP60, LRPPRC, and
TUFM was investigated in mitochondrial fractions from
control and PINK1-mutant ﬁbroblasts. This experiment
revealed comparable levels of GRP75, HSP60, and LRPPRC
in both groups (Figures 3(a) and 3(b)-left half). The
abundance of TUFM was variable in all investigated samples
showing no clear trend when comparing mutants and
controls (Figure 3(a)).
Furthermore, we tested the quality of the GRP75 anti-
body by investigating GRP75 in the cytosolic fraction under
valinomycin stress conditions. GRP75 is a mitochondrial
matrix chaperone, synthesized as a 679-amino acid prepro-
tein, which contains a 51-residue N-terminal mitochondrial
targeting sequence (MTS). After the membrane potential-
dependent import into mitochondria, it is cleaved into the
mature protein which is ∼5.5kDa shorter than the prepro-
tein [23–25]. When treating cells with the mitochondrial
membrane potential inhibitor valinomycin, the full-length
form of GRP75 (MTS-GRP75) was detected in the cytosolic
fractions from mutants and controls. Consequently, we con-
sidered the anti-GRP75 antibody as speciﬁc. In both groups,
the levels of MTS-GRP75 were comparable (Figure 3(b)-
right half). The abundance of the processed form of GRP75
inthecytosolicfraction was likelyduetocontamination with
the mitochondrial fraction, although previous studies have
shown that GRP75 can also be cytosolically localized [26].
Though our Western blot results are not supporting a
direct link between PINK1 and any of the detected mito-
chondrial proteins, it should be noted that GRP75, HSP60,
and LRPPRC have been identiﬁed by proteomic analysis
as potential interactors of Parkin earlier [27]. Furthermore,
their molecular functions render them interesting targets in
the context of PD.
GRP75 serves as a major mitochondrial molecular chap-
erone and plays a key role in the import and partitioning
of nuclear-encoded proteins within the two mitochondrial
membranes and the matrix [28–30]. Furthermore, GRP75
seems to function in the management of oxidative stress
via the PD-associated protein DJ-1. Mutations in DJ-1 were
found to weaken the protein’s interaction with GRP75 [31,
32]. GRP75 has also been described as an antiapoptotic
agent. By binding of the transcription regulator p53, GRP75
preventsthe formation of the proapoptotic p53/Bcl-xL/Bcl-2
complex[33,34].Furthermore,putativemutationsinGRP75
were suggested to contribute to the risk of developing PD
[35] and a decrease in GRP75 expression was detected in PD
patient brains compared to controls [36].
HSP60 is a mitochondrial chaperone responsible for the
transport of nuclear-encoded proteins via the mitochondrial
membranes and their refolding in the matrix [37, 38]a n d
has been linked to the pathogenesis of Alzheimer’s disease.
Apparently, HSP60 provides protection against intracellular
β-amyloid stress through maintenance of mitochondrial
respiratory complex IV activity [39]. Complex IV deﬁciency
in turn, has been implicated in PD [40, 41] opening the
possibility for a role of HSP60 in the pathogenesis of the
disease.
LRPPRC has been linked to cytochrome C oxidase
deﬁciency. Mutations in the gene lower MT-CO1 and MT-
CO3 mRNA levels and, in turn, impair complex IV assembly
[42,43].Recentfunctionalstudiesfurtherstrengthenthelink
between LRPPRC and mitochondrial RNA metabolism [44,
45]. However, when we compared MT-CO1 protein levels in
ﬁbroblasts from PINK1 mutants and controls, no diﬀerences
were observed (Figure 3(a)). Furthermore, LRPPRC was
identiﬁed as a component of the PGC-1α complex which
itselfisalsolinkedtoenergyhomeostasis inthecell[46].Like
in the case of HSP60, LRPPRC’s impact on the respiratory
chain oﬀers a potential connection with PD.
TUFM is part of the translational apparatus of mito-
chondria. During protein biosynthesis, it mediates the GTP-
dependent binding of aminoacyl-tRNA to the A-site of
ribosomes [47]. Additional described functions of TUFM
comprise recognition and translocation of cotranslationally
damaged proteins to the proteasome [48], rearrangement
of cytoskeletal components [49, 50], and regulation of cell
survival [51]. Mutations in the TUFM gene cause combined
oxidativephosphorylation deﬁciencytype4 dueto decreased
mitochondrial protein synthesis [52]. Interestingly, however,
there is also a report connecting TUFM and PD, where
TUFMwas foundtoco-immunoprecipitatewith Leucin-rich
repeat kinase 2 which is encoded by the PARK8 gene LRRK2.
Coincubation with recombinant TUFM reduced the kinase6 Parkinson’s Disease
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Figure 3:Cellularabundanceofpotential mitochondrialPINK1-interactingproteins.Mitochondrial andcytosolicfractionsfromﬁbroblasts
were analyzed by Western blotting using antibodies against HSP60, LRPPRC, TUFM, MT-CO1, and GRP75. (a) The mitochondrial
localization of LRPPRC and TUFM was conﬁrmed, and no diﬀerences in their cellular abundance were detected when comparing PINK1
mutants and controls. Furthermore, the level of LRPPRC-associated MT-CO1 was not altered in PINK1 mutants. (b) In the mitochondrial
fractions, the abundance of (processed) GRP75 was comparable in PINK1 mutants and controls under basal and valinomycin stress
conditions (1μM for 24h). In the cytosol, an additional band representative of accumulation of nonprocessed MTS-GRP75 was detected
when cells were treated with the mitochondrial membrane inhibitor valinomycin. Due to a possible contaminationof the cytosolic fraction
with mitochondria and/or partially cytosolic localization of GRP75, also the processed form of the protein is apparent in this fraction.
The mitochondrial marker VDAC1 and the cytosolic marker β-actin served as loading controls. GRP75: 75kDa glucose-regulated protein;
HSP60: Heat shock 60kDa protein; LRPPRC: Leucine-rich PPR motif-containing protein; MT-CO1: Mitochondrially encoded cytochrome
c oxidase I; MTS-GRP75: GRP75 with mitochondrial targeting sequence; TUFM: Elongation factor Tu; VDAC1: Voltage-dependent anion
channel 1.Parkinson’s Disease 7
Table 2: Allelic frequencies of sequence variations identiﬁed in LRPPRC.
Gene position DNA variation NCBI no. AF PD AF DB Database∗
5 UTR c.-45G>A rs11124961 7.6% 1.4% pilot.1.CEU
Exon 2 c.246G>A (p.Q82Q) rs6741066 66.7% 65.5% HapMap-CEU
Intron 3 IVS3-132C>G rs6721144 6.8% 13.3% HapMap-CEU
Intron 6 IVS6-70T>C rs17031786 14.4% 13.8% HapMap-CEU
Exon 9 c.1068A>G (p.Q356Q) rs4953042 16.3% 19.2% HapMap-CEU
Intron 9 IVS9+30A>G rs7593842 15.2% 12.7% HapMap-CEU
Intron 13 IVS13+28T>C rs62135104 9.5% 1.5% pilot.1.CEU
Intron 15 IVS15+11C>G rs58811869 7.8% 13.9% pilot.1.CEU
Intron 17 IVS17-28T>G rs72877186 15.2% 15.3% pilot.1.CEU
Intron 20 IVS20-40A>C rs7594526 42.4% 47.5% HapMap-CEU
Intron 22 IVS22+27T>G rs28394191 43.5% 40.3% pilot.1.CEU
Exon 23 c.2481A>G (p.P827P) rs115993634 1.1% none none
Intron 27 IVS27+26C>T rs4952694 51.1% 53.0% AoD Caucasian
Intron 27 IVS27-38A>G none 2.2% none none
Intron 28 IVS28+21C>A rs7568481 43.5% 47.4% HapMap-CEU
Intron 30 IVS30+97T>C rs17424482 8.7% 3.7% HapMap-CEU
Intron 32 IVS32-3C>T rs35113761 6.5% none none
Intron 35 IVS35+14C>T rs3795859 15.2% 15.0% HapMap-CEU
Intron 35 IVS35+15C>T rs76850904 8.7% none none
Intron 36 IVS36-42G>C none 1.1% none none
Exon 37 c.4023T>C (p.Y1341Y) none 1.1% none none
Intron 37 IVS37+37G>A rs2955280 51.1% 53.4% HapMap-CEU
3 UTR ∗399G>A none 2.3% none none
3 UTR ∗556A>T rs1136998 7.6% 8.3% HapMap-CEU
Note: AF: allelic frequency, DB: database, PD: Parkinson’s disease and ∗Only studies based on European populations included.
activity of LRRK2, whereas the GTPase activity remained
unchanged [53].
3.3. LRPPRC Mutational Screen. Among the identiﬁed
PINK1 interactors, LRPPRC is the only protein which
is unequivocally linked to a neurodegenerative disorder.
Mutations in LRPPRC are the cause of the French-Canadian
type of Leigh syndrome (LSFC). LSFC patients suﬀer from
progressive focal necrotizing lesions of the brainstem, basal
ganglia, and cerebellum, accompanied by capillary prolifera-
tion.Besidesmetabolicacidosis,clinicalfeaturesincludegen-
eralized developmental delay, cerebellar signs, and a striking
paucity of facial and limb movement, as well as hypomimia
[46]. Given the presence of Parkinsonian signs in LSFC
patients, we decided to sequence the 38 exons and ﬂanking
intronic regions of LRPPRC in 46 patients with atypical
PD with early onset and/or rapid disease progression and
dementia. This mutational screen revealed 24 substitutions;
four of which have not yet been reported in any database
(Table 2). Four synonymous variations were detected in the
coding region (c.246G>A[p.Q82Q],c.1068A>G[p.Q356Q],
c.2481A>G [p.P827P], c.4023T>C [p.Y1341Y]). Seventeen
changes were found in introns, one in the 5 UTR and two
in the 3 UTR. The frequencies of most substitutions in our
sample were similar to those reported in the NCBI SNP
database (http://www.ncbi.nlm.nih.gov/) for studies based
on populations of European origin, such as pilot.1.CEU,
HapMap-CEU, and AoD Caucasian. Interestingly, frequen-
cies of SNPs c.-45G>A, IVS13+28T>C and IVS30+97T>C,
were markedly higher than those reported in the databases.
The signiﬁcance of this ﬁnding needs to be investigated in
a larger sample. The screening techniques used here allow,
however, only for the identiﬁcation of qualitative sequence
changes. Therefore, although no single nucleotidechanges of
likely pathogenic relevance have been found in the LRPPRC
gene, gene dosage variations cannot be excluded.
4.Conclusions
In the current study, TAP technology was employed for
the ﬁrst time to identify PINK1-associated proteins. These
experiments resulted in a list of 14 putative PINK1 binding
partners, conﬁrming two reported interactions (HSP90 and
CDC37), but also introducing four novel mitochondrially
localized proteins (GRP75, HSP60, LRPPRC, or TUFM)
as potential components of the PINK1/Parkin mitophagy
pathway. Although preliminary results from protein expres-
sion and DNA sequencing analyses do not strengthen a
link between the PINK1/Parkin pathway and any of these
interactors, it cannot be excluded that their connection8 Parkinson’s Disease
with the pathway may be more complex. Additional protein
function studies, for instance under mitochondrial stress
conditions, will be needed to fully characterize this potential
link. In addition, future perspectives include association
studieswithSNPsinallidentiﬁedgenesinalargerPDpatient
sample.
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